BioXcel Therapeutics Inc (BTAI) - Margin bathi reged

BTAI (BioXcel Therapeutics Corp) - tandha merek perusahaan

Stable raw material supplies ensure the operational reliability of BioXcel Therapeutics. The gross profit margin reflects cost dynamics, where the value of 22.80 represents the most recent figure. Growth is driven by the expansion of the drug Igalmi and AI technologies, although high expenses and regulatory risks threaten the company's financial stability.

BTAI: Margin reged BioXcel Therapeutics, Inc. 04.07.2022 - 19.09.2026

Rincian metrik komprehensif lan analitis BioXcel Therapeutics, Inc. (BTAI)

- rega pasar lan target rega analis:
Produk mawa merek bioxceltherapeutics.com

Gross margin is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, determining direct production efficiency and internal profitability potential. For BioXcel Therapeutics (BTAI), this indicator reflects the economic return from applying AI in drug repositioning, allowing for an assessment of the therapy's commercial viability through the stability of the gross margin.